Why Choose Us?

Let China use globally innovative vaccines, and let the world use high-quality vaccines from China!

quanfu quanfu

Strong Corporate Strength

The registered capital is 360 million yuan, the investment in Phase I project is 500 million yuan, the investment in Phase II project is 500 million yuan, and the new investment in Phase III is 2 billion yuan

quanfu quanfu

Products & Services

Committed to the research and development, registration and application, industrial production and sales of innovative vaccines for human use, targeting international standards, and conducting independent innovative research and development.

quanfu quanfu

Scientific Research Capability

Shanghai/Taizhou R&D Center and pilot platform are promoting multiple viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccine pipelines simultaneously.

Product Pipelines

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Quadrivalent Subunit Influenza Vaccine(0.5ml)

Quadrivalent Subunit Influenza Vaccine: the components of the 2018-2019 northern hemisphere tetravalent influenza vaccine recommended by WHO are: A / Michigan / 45 / 2015 (H1N1) pdm09 similar strain, a / Singapore / infimh-16-0019 / 2016 (H3N2) similar strain, B / Colorado / 06 / 2017 (Victoria strain) similar strain and B / Phuket / 3073 / 2013 (Yamagata strain).

More Product Series

News Center

2024-2025 Flu Season Huilconxin Approved for Signing On

2024-06-12

On June 12, 2024, China Wisdom Bio's quadrivalent influenza virus subunit vaccine Huir Kangxin for the 2024-2025 influenza season received the Certificate of Approval and Issue of Biological Products issued by the State Drug Administration, which is still exclusive in China, and will be quickly dispatched to the whole country to guard the health of the Chinese people.

Influenza virus subunit vaccine application accepted!

2024-06-07

On June 7, 2024, Jiangsu Zhonghui Yuantong Bio-technology Co., Ltd (hereinafter referred to as “Zhonghui Bio”) declared that the application for “Influenza Virus Subunit Vaccine” was accepted by the Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (CDE).

Huilkangxin Receives Registration Approval from the Drug Administration of Macau

2024-05-17

On May 10, 2024, Jiangsu Zhonghui Yuantong Bio-Technology Co., Ltd (hereinafter referred to as “Zhonghui Bio”) received registration approval from the Drug Administration of the Government of the Macao Special Administrative Region (Macao SAR) for its full-dose, adjuvant-free quadrivalent influenza virus subunit vaccine (Huilkangxin HRK-X®), which is intended for use in people 3 years of age and older.

Have a project?Get a touch!

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Contact

E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Search